Amgen Inc. (NASDAQ:AMGN) EVP Murdo Gordon Sells 8,771 Shares

Amgen Inc. (NASDAQ:AMGN) EVP Murdo Gordon sold 8,771 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amgen Stock Performance

AMGN opened at $291.16 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 9.62. The firm has a market capitalization of $156.51 billion, a PE ratio of 38.56, a P/E/G ratio of 3.01 and a beta of 0.56. The firm has a 50 day moving average of $273.75 and a two-hundred day moving average of $302.14.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts anticipate that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.27%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is 126.09%.

Hedge Funds Weigh In On Amgen

Institutional investors have recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new position in shares of Amgen during the 3rd quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 3rd quarter valued at $29,000. Centricity Wealth Management LLC acquired a new stake in Amgen in the 4th quarter valued at $25,000. Ritter Daniher Financial Advisory LLC DE grew its stake in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 51 shares during the period. Finally, Synergy Investment Management LLC acquired a new stake in Amgen in the 4th quarter valued at $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AMGN has been the topic of several recent research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Piper Sandler Companies reiterated an “overweight” rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Wells Fargo & Company dropped their target price on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Finally, Leerink Partners dropped their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $314.09.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.